In today’s business climate, medical device and life sciences companies need to be properly positioned at each phase of development with the appropriate plans in place for later portfolio development stages. Panelists will review key business and intellectual property management tools and strategies that are needed at the early-, mid- and late-growth stages as well the types of funding needed to fuel growth throughout the product life cycle. We also will address how and when you should plan for an IPO as well as other exit strategies, including merger and acquisitions.
Topics include:
- How companies can balance the need to continually innovate while minimizing the failure rate
- How to realize revenue streams earlier in the process
- How to evaluate innovation based on potential business value
Panelists:
- Jeff Draa, Board of Directors, Tech Coast Angels
- Gabor Garai, Partner, Foley & Lardner
- Vanessa Herbert, Senior Manager, PricewaterhouseCoopers
- Keith Lindenbaum, Partner, Foley & Lardner LLP
- Robert Mashal, M.D., President & CEO, NKT Therapeutics
- David Parrot, M.B.A., Managing Director, BMO Capital Markets Corp.
Related Insights
April 3, 2026
Energy Current
Texas Legislature Sets Its Sights on Data Centers and AI: What You Need to Know
Texas House and Senate leadership recently released their interim charges, which serve as "homework assignments" for legislative…
April 3, 2026
Foley Viewpoints
For Your Eyes Only? Not Quite: Shadow AI in the Workplace
While many companies are still developing governance frameworks for authorized AI tools, an emerging risk has quietly surfaced: employees using unauthorized transcription tools without the company’s or participants’ consent.
April 3, 2026
Manufacturing Industry Advisor
Connecticut Appellate Court Narrows Scope of Petroleum “Franchise” Protections for Gas Station Operators
The Appellate Court of Connecticut affirmed a trial court’s judgment in favor of a petroleum distributor/lessor, holding that convenience…